Concepedia

Naoyuki Asakawa

NA

Statistics

Publications

18

Citations

608

H-Index

14

Active since

1994

Affiliations

Bristol-Myers Squibb (United States)(Current)

Yakult Central Institute

Yakult Honsha (Japan)

Bristol-Myers Squibb (Germany)

University of Shizuoka

Naoyuki Asakawa is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, medicinal chemistry, and drug discovery.

Publications per year

1994–2020

18

Publications

18

SOSUI-GramN: high performance prediction for sub-cellular localization of proteins in Gram-negative bacteria

Kenichiro Imai, Naoyuki Asakawa, Toshiyuki Tsuji et al. · Bioinformation · 2008 · 129 citations · Full text

, , +14

Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen

Akinobu Kurita, Shoichi Kado, Tsuneo Matsumoto et al. · Cancer Chemotherapy and Pharmacology · 2010 · 64 citations

, , +8

Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-α converting enzyme (TACE)

James J.‐W. Duan, Lihua Chen, Zhonghui Lu et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 53 citations · Full text

, , +11

Potent, exceptionally selective, orally bioavailable inhibitors of TNF-α Converting Enzyme (TACE): Novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1′ substituents

Gregory R. Ott, Naoyuki Asakawa, Zhonghui Lu et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 46 citations · Full text

, , +11

Novel Acrylonitrile Derivatives, YHO-13177 and YHO-13351, Reverse BCRP/ABCG2-Mediated Drug Resistance<i>In Vitro</i>and<i>In Vivo</i>

Ryuta Yamazaki, Yukiko Nishiyama, T Furuta et al. · Molecular Cancer Therapeutics · 2011 · 45 citations · Full text

, , +11

1–5 of 18